# NeuroEbola

> **NIH NIH R01** · OREGON HEALTH & SCIENCE UNIVERSITY · 2022 · $533,740

## Abstract

SUMMARY
Ebolaviruses (EBOV) are among the deadliest pathogens known to man, with a case fatality rate of 25–90%
depending on the outbreak. For the first time, monoclonal antibodies Zmapp, Mab114, REGN-EB3 and
Remdesivir (inhibitor of viral RNA synthesis) were used, improving survival rates in Ebola treatment units
(ETU) during the ongoing outbreak of Ebola virus disease (EVD) in Congo-Kinshasa. Despite treatments, 34%
of EVD survivors experienced eye complications. In addition, they had lower [mean (SD)] minimental test
examination (MMSE) scores i.e. [25 (5.5)] relative to controls [29.9 (0.6)] (p < 0.01); and women perform poorly
[24.8 (5.90] relative to men [28.4 (3.2)](p < 0.01). The odds of depression were higher in EVD survivors [OR:
14.9 (95%CI: 4.4 – 50.1)], mostly in women [OR: 4.4. (95%CI: 2.1 – 9.6)] and, intriguingly, MMSE deficit in
women was associated with higher initial EBOV viral load [OR: 0.84 (95%CI: 0.73 – 0.98, p = 0.03, for one-unit
increase in ctXptNP; lower ctXpt = higher viral load] after adjustment for age and depression status. EBOV
persisted in breastmilk, wet preps, and semen for several months after acute EVD. We propose to test the
hypothesis that occurrence of neuroophthalmologic sequalae is dictated by initial and/or persistence of EBOV
viral load with discernable IgG responses, and/or a persistent inflammatory state driven by elevated cytokines
and immune cell activation; by addressing the following specific aims: Aim 1. To contrast neuro-
ophthalmologic deficits (spectrum & extent) found in confirmed EVD survivors to relevant profiles seen in their
IgG+ but EVD-free close contacts, and IgG- controls (N = 90 per group). In Aim 1A, study participants will
have longitudinal (0, 6, 12, 24, 36, and 48 month-time-points) assessments of neurocognition using the
computerized Test of Variables of Attention (auditory and visual), the Test of Attentional Performance, and
CogState for nonverbal cognitive skills. In Aim 1B, they will undergo psychophysical tests for visual acuity,
contrast sensitivity, color vision, and visual field; as well as spectral domain-optical coherence tomography to
elucidate structural biomarkers of disease within visual pathways. Aim
differences
levels
overabundance
2 will determine whether group-
on neuroophthalmologic outcomes found in Aim 1 are mediated by EBOV viral load or persistence,
of anti-EBOV IgG, alterations in levels or activation status of circulating immune cells, and/or
of proinflammatory cytokines. Aim 3 will enhance capacity in neurocognitive assessments,
ophthalmologic evaluations and EVD immunoprofiling and molecular biology (RT-PCR). Gaps of knowledge to
be filled include lack of understanding of (1) EBOV persistence, (2) long-lasting immune dysregulation, (3) IgG
positivity with no overt EVD symptoms, all in contexts of post-EVD treatment. The overall goal of the proposed
work aligns with the global health mission of the NIH while integrating the institute-specific missions of...

## Key facts

- **NIH application ID:** 10486134
- **Project number:** 5R01EY031894-02
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** JEAN-CLAUDE MWANZA
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $533,740
- **Award type:** 5
- **Project period:** 2021-09-30 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10486134

## Citation

> US National Institutes of Health, RePORTER application 10486134, NeuroEbola (5R01EY031894-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10486134. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*